Edition:
United Kingdom

Neos Therapeutics Inc (NEOS.OQ)

NEOS.OQ on NASDAQ Stock Exchange Global Market

10.00USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$10.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
164,812
52-wk High
$13.15
52-wk Low
$4.85

Latest Key Developments (Source: Significant Developments)

PDL Biopharma urges Neos Therapeutics to provide update on sale process
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - PDL Biopharma :PDL Biopharma's proposal to acquire Neos Therapeutics expires today; PDL urges Neos to provide update on sale process.Reiterated that its proposal to acquire Neos Therapeutics Inc for $10.25 per share in cash will expire today at market close​.Decided it will not extend deadline for, or otherwise alter, its proposal​.  Full Article

Neos Therapeutics reports Q3 loss of $0.58/shr
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Neos Therapeutics Inc :Neos Therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.58.Q3 earnings per share view $-0.75 -- Thomson Reuters I/B/E/S.Neos Therapeutics Inc - ‍total product revenues were $6.7 million for three months ended September 30, 2017, compared to $1.6 million for same period in 2016​.Q3 earnings per share view $-0.75, revenue view $6.6 million -- Thomson Reuters I/B/E/S.  Full Article

Neos Therapeutics receives paragraph IV certification from Teva Pharmaceuticals USA
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Neos Therapeutics Inc ::Neos Therapeutics-co received paragraph iv certification from teva pharmaceuticals usa that teva submitted anda for generic version of cotempla xr-odt​.Neos - notice alleges that 3 U.S. Patents in FDA's orange book for cotempla XR-ODT will not be infringed by Teva's generic version of cotempla XR-ODT.Neos - is evaluating paragraph IV certification from Teva Pharmaceuticals USA, intends to "vigorously enforce" ip rights relating to cotempla XR-ODT​.  Full Article

PDL Biopharma issues response to Neos Therapeutics rejection of PDL acquisition proposal
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Pdl Biopharma Inc :PDL Biopharma issues statement in response to Neos Therapeutics rejection of PDL acquisition proposal.PDL Biopharma Inc - ‍PDL's proposal to Neos remains outstanding through November 8, 2017 & co will evaluate "all of its options" in interim​.  Full Article

Neos Therapeutics‍ confirms it got unsolicited proposal from PDL Biopharma
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Neos Therapeutics Inc ::Says confirmed it received unsolicited proposal from PDL Biopharma to buy co for $10.25 per share in cash​.Says Neos board will respond to PDL proposal received on Oct 26 in due course​.  Full Article

PDL BioPharma proposes to acquire Neos Therapeutics for $10.25 per share
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Pdl Biopharma Inc :PDL Biopharma proposes to acquire NEOS THERAPEUTICS for $10.25 per share in cash.PDL Biopharma Inc - ‍PDL proposal is not subject to any financing conditions​.PDL Biopharma Inc - ‍PDL proposal will remain outstanding for a period of fourteen days​.PDL BioPharma Inc - ‍on June 23, 2017, PDL formally proposed to acquire Neos for $10.25 per share, a proposal Neos Board promptly rejected​.PDL BioPharma Inc - ‍reconfirming proposal to purchase Neos Therapeutics for a cash purchase price of $10.25 per share​.PDL BioPharma Inc - ‍following Neos' dilutive financing at $6.25 per share, PDL maintained its $10.25 proposal to Board​.  Full Article

Neos Therapeutics Qtrly loss per share $1.65
Thursday, 11 Aug 2016 

Neos Therapeutics Inc : Neos Therapeutics announces second quarter 2016 financial results . Q2 revenue $1.5 million .Q2 revenue view $1.9 million -- Thomson Reuters I/B/E/S.  Full Article

Neos therapeutics files for mixed shelf of up to $125 million - sec filing
Monday, 1 Aug 2016 

Neos Therapeutics Inc :Files for mixed shelf of up to $125 million - sec filing.  Full Article

Neos Therapeutics Q1 revenue $2.6 million
Monday, 16 May 2016 

Neos Therapeutics Inc : Neos Therapeutics Inc qtrly net loss per share attributable to common stock, basic and diluted $0.79 . Q1 earnings per share view $-0.86 -- Thomson Reuters I/B/E/S . Neos Therapeutics announces closing of $60 million term debt financing and first quarter 2016 financial results . Q1 revenue $2.6 million .Q1 revenue view $800,000 -- Thomson Reuters I/B/E/S.  Full Article

Neos Therapeutics says Adzenys XR-ODT is available to prescribe to patients with ADHD in United States
Monday, 16 May 2016 

Neos Therapeutics Inc :Adzenys xr-odt is in distribution channels and is now available to prescribe to patients with ADHD in United States.  Full Article

BRIEF-Neos Therapeutics reports Q3 loss of $0.58/shr

* Neos Therapeutics reports third quarter 2017 financial results